EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application (NDA) for Fintepla® (ZX008,…Original Article
Zogenix Resubmits New Drug Application for Fintepla for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
